{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:34:34Z","timestamp":1793421274036,"version":"4.5.0"},"reference-count":54,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070809"],"award-info":[{"award-number":["82070809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2024AFB660"],"award-info":[{"award-number":["2024AFB660"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Graves orbitopathy is a specialized immunoinflammatory disorder related to abnormal thyroid function. Due to the complexity of the disease and its propensity to reoccur, targeted treatment is essential to improve the symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aims to assess the efficacy and safety of various treatments for active thyroid eye disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a comprehensive search for randomized controlled trials (RCTs), and ongoing RCTs registered on Controlled Trials, targeting treatments for thyroid eye disease until November 20, 2024. Employing a Bayesian framework, this network meta-analysis calculated risk ratios (RRs) or mean differences (MDs) with 95% CIs to size the effects for the predetermined outcomes. The study is registered with PROSPERO (CRD42024548030).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome<\/jats:title>\n                  <jats:p>The primary outcomes evaluated were overall response rate, clinical activity score (CAS), proptosis, diplopia, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For the overall response rate, teprotumumab (RR 5.5, 95% CI 2.3 to 16), mycophenolate combined intravenous glucocorticosteroids (IVGCs) demonstrated effectiveness over no treatment, ranked from most to least effective. Notably, teprotumumab showed the highest efficacy in reducing CAS (MD \u22121.57, 95% CI \u22123.81 to 0.68) and proptosis (MD \u22122.29, 95% CI \u22122.73 to \u22121.86). For diplopia improvement, teprotumumab and IVGCs were effective compared with no treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Teprotumumab emerges as potentially the most effective treatment for reducing inflammation and increasing overall response rates when compared with no treatment; oral mycophenolate combined with IVGCs appears to be the best for improving proptosis. While some treatments raise safety concerns due to reported adverse events, oral methotrexate combined with IVGCs appear to offer a favorable balance between efficacy and safety among the evaluated treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae877","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:31:32Z","timestamp":1734373892000},"page":"1792-1801","source":"Crossref","is-referenced-by-count":15,"title":["Comprehensive Comparisons of Different Treatments for Active Graves Orbitopathy: A Systematic Review and Bayesian Model\u2013Based Network Meta-Analysis"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3889-4222","authenticated-orcid":false,"given":"Yanlin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-0997","authenticated-orcid":false,"given":"Jiaoyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]},{"name":"Hubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"1","key":"2025052713010271300_dgae877-B1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cxo.12472","article-title":"Thyroid eye disease: a review","volume":"100","author":"Weiler","year":"2017","journal-title":"Clin Exp Optom"},{"issue":"8","key":"2025052713010271300_dgae877-B2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"2025052713010271300_dgae877-B3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","article-title":"Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves\u2019 ophthalmopathy","volume":"142","author":"Dik","year":"2016","journal-title":"Exp Eye Res"},{"issue":"4","key":"2025052713010271300_dgae877-B4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/01676831003668443","article-title":"The orbital fibroblast: a key player and target for therapy in graves\u2019 ophthalmopathy","volume":"29","author":"van Steensel","year":"2010","journal-title":"Orbit"},{"issue":"11","key":"2025052713010271300_dgae877-B5","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1167\/iovs.18-24509","article-title":"Inhibitory effect of idelalisib, a selective phosphatidylinositol 3-kinase \u03b4 inhibitor, on adipogenesis in an in vitro model of Graves\u2019 orbitopathy","volume":"59","author":"Ko","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025052713010271300_dgae877-B6","doi-asserted-by":"crossref","first-page":"2042018820958335","DOI":"10.1177\/2042018820958335","article-title":"Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application","volume":"11","author":"L\u00e4ngericht","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"2025052713010271300_dgae877-B7","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025052713010271300_dgae877-B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European thyroid association\/European group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"2025052713010271300_dgae877-B9","first-page":"167","article-title":"Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025052713010271300_dgae877-B10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"18","key":"2025052713010271300_dgae877-B11","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025052713010271300_dgae877-B12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjophthalmol-2018-313697","article-title":"Treatment strategies for Graves\u2019 ophthalmopathy: a network meta-analysis","volume":"104","author":"Zhou","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"7\u20138","key":"2025052713010271300_dgae877-B13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"2","key":"2025052713010271300_dgae877-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7521","key":"2025052713010271300_dgae877-B15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"2025052713010271300_dgae877-B16","doi-asserted-by":"crossref","unstructured":"Xu YL, Zhang JY, Liu RK, et al \u00a02024. Supplementary appendix for Comprehensive Comparisons of Different Treatments for Active Graves\u2019 Orbitopathy: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. Mendeley Data, V1. doi: 10.17632\/hwjwys3k3b.1.","DOI":"10.1210\/clinem\/dgae877"},{"key":"2025052713010271300_dgae877-B17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"2025052713010271300_dgae877-B18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"2025052713010271300_dgae877-B19","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052713010271300_dgae877-B20","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2025052713010271300_dgae877-B21","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"2025052713010271300_dgae877-B22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/027298902400448920","article-title":"Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty","volume":"22","author":"Ades","year":"2002","journal-title":"Med Decis Making"},{"key":"2025052713010271300_dgae877-B23","doi-asserted-by":"crossref","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"7414","key":"2025052713010271300_dgae877-B24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2025052713010271300_dgae877-B25","doi-asserted-by":"crossref","first-page":"g1741","DOI":"10.1136\/bmj.g1741","article-title":"Reporting of results from network meta-analyses: methodological systematic review","volume":"348","author":"Bafeta","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"2025052713010271300_dgae877-B26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10384-023-01016-4","article-title":"Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial","volume":"67","author":"Swaify","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"2025052713010271300_dgae877-B27","doi-asserted-by":"crossref","first-page":"1140196","DOI":"10.3389\/fendo.2023.1140196","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2025052713010271300_dgae877-B28","doi-asserted-by":"crossref","first-page":"e220017","DOI":"10.1530\/ETJ-22-0017","article-title":"Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves\u2019 orbitopathy","volume":"11","author":"Shen","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"4","key":"2025052713010271300_dgae877-B29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025052713010271300_dgae877-B30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3\u20134","key":"2025052713010271300_dgae877-B31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000453618","article-title":"The efficacy of rituximab combined with 131I for ophthalmic outcomes of Graves\u2019 ophthalmopathy patients","volume":"99","author":"Li","year":"2017","journal-title":"Pharmacology"},{"issue":"2","key":"2025052713010271300_dgae877-B32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025052713010271300_dgae877-B33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052713010271300_dgae877-B34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/2230-8210.152770","article-title":"Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves\u2019 orbitopathy: a randomized controlled trial","volume":"19","author":"Roy","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"2025052713010271300_dgae877-B35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","article-title":"Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy","volume":"38","author":"Alkawas","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"2025052713010271300_dgae877-B36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025052713010271300_dgae877-B37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy","volume":"61","author":"Aktaran","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"9","key":"2025052713010271300_dgae877-B38","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025052713010271300_dgae877-B39","first-page":"322","article-title":"Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves\u2019 ophthalmopathy: a preliminary study","volume":"11","author":"Ng","year":"2005","journal-title":"Hong Kong Med J"},{"issue":"1","key":"2025052713010271300_dgae877-B40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy","volume":"89","author":"Prummel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025052713010271300_dgae877-B41","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025052713010271300_dgae877-B42","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy","volume":"108","author":"Gorman","year":"2001","journal-title":"Ophthalmology"},{"issue":"9214","key":"2025052713010271300_dgae877-B43","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study","volume":"355","author":"Mourits","year":"2000","journal-title":"Lancet"},{"issue":"Suppl_1","key":"2025052713010271300_dgae877-B44","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025052713010271300_dgae877-B45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2025052713010271300_dgae877-B46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease: a multicenter study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"},{"issue":"11","key":"2025052713010271300_dgae877-B47","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"2025052713010271300_dgae877-B48","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"issue":"2 Suppl","key":"2025052713010271300_dgae877-B49","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"2025052713010271300_dgae877-B50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2025052713010271300_dgae877-B51","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for graves\u2019 orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4S Suppl 1","key":"2025052713010271300_dgae877-B52","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/IOP.0000000000001074","article-title":"Radiotherapy for active thyroid eye disease","volume":"34","author":"Godfrey","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"2025052713010271300_dgae877-B53","first-page":"422","article-title":"Methotrexate as a corticosteroid-sparing agent for thyroid eye disease","volume":"6","author":"Rivera-Grana","year":"2015","journal-title":"J Clin Exp Ophthalmol"},{"issue":"6","key":"2025052713010271300_dgae877-B54","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1111\/aos.15074","article-title":"Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves\u2019 orbitopathy: a systematic review and network meta-analysis","volume":"100","author":"Li","year":"2022","journal-title":"Acta Ophthalmol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae877\/61203570\/dgae877.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/1792\/61203570\/dgae877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/1792\/61203570\/dgae877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:03:38Z","timestamp":1748365418000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/6\/1792\/7925787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae877","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,16]]}}}